Session 2: A Comprehensive, Evidence-Based Review of Anticoagulation

Date: 8/9/2012 Check-In

*Hotel Breakfast Buffet

6:00 - 7:30 am

Educational Session: 7:30 am - 1:00 pm
Kelly W. Jones, Pharm. D., BCPS Associate Professor of Family Medicine, Department of Family Medicine, McLeod Regional Medical Center, Florence, South Carolina., Live CME Instructor for University Learning Systems
Kelly W. Jones, Pharm. D., BCPS Associate Professor of Family Medicine, Department of Family Medicine, McLeod Regional Medical Center, Florence, South Carolina; Adjunct Associate Professor and Adjunct Clinical Assistant Professor, Department of Community Pharmacy Practice and Administration, Medical University of South Carolina, Charleston, South Carolina. Disclosure: Dr. Jones has NO financial arrangements with any corporate organization that might have an interest in the subject being presented.
At the conclusion of this program, the participant will be able to:


  1. Discuss the philosophical concepts of Evidence-Based Medicine (EBM) and how these principles can be applied to the medical decision making process in patients taking anticoagulation therapy.
  2. Discuss the different type of research papers that provide outcomes that change the practitioner’s practice of medicine (disease-oriented vs. patient oriented). This principle will be applied to research in anticoagulation therapy.
  3. Describe the concepts of relative risk reduction, absolute risk reduction, numbers needed to treat and numbers needed to harm and how these statistical measures can affect the data interpretation of anticoagulation studies.
  4. Discuss the benefit and harm of aspirin for the primary prevention and secondary prevention of cardiovascular disease using evidence based research.
  5. Discuss the appropriate dose of aspirin.
  6. Discuss other antiplatelet therapy (clopidogrel, dipyridamole and aspirin, prasugrel) for primary care and the benefit in the primary and secondary prevention of stroke and heart attack.
  7. Discuss a comprehensive review of warfarin, detailing the medications history, pharmacotherapy, pharmacokinetics, side effects and drug interactions.
  8. Discuss new evidence (POEMS) surrounding anticoagulants. Trials to be discussed, but not limited to: ACTIVE-A, ACTIVE-W, WARSS, CAPRIE, CHARISMA, MATCH, ESPS-2, CURE, BDTA, ASA Prevention Study.
  9. Discuss any new medications that come to market, using the safety, tolerability, efficacy, price and simplicity format (STEPS).